Skip to main content

Marsico Lung Institute Publications for October 2023

By

Marsico Lung Institute faculty, postdoc, student, and collaborator publications for October 2023 included papers appearing in Lancet Respiratory Medicine, Nature Chemistry, and Nature Microbiology. Check out the full list below:

  1. Casadevall A, Cotter PA, Enquist L, Donohue TJ, Bertuzzi S, Nguyen NK. An account of American Academy of Microbiology reforms and pandemic operations. mBio. 2023 Oct 26:e0233423. doi: 10.1128/mbio.02334-23. Epub ahead of print. PMID: 37882546.
  2. Rydberg M, Burkett P, Johnson E, Drummond MB. Home Telemonitoring Program in Individuals with COPD During the Coronavirus Disease 2019 Pandemic: A Pilot Study. Chronic Obstr Pulm Dis. 2023 Oct 26;10(4):437-443. doi: 10.15326/jcopdf.2023.0431. PMID: 37552509.
  3. Sopha P, Meerod T, Chantrathonkul B, Phutubtim N, Cyr DM, Govitrapong P. Novel functions of the ER-located Hsp40s DNAJB12 and DNAJB14 on proteins at the outer mitochondrial membrane under stress mediated by CCCP. Mol Cell Biochem. 2023 Oct 18. doi: 10.1007/s11010-023-04866-1. Epub ahead of print. PMID: 37851175.
  4. Donoghue LJ, Markovetz MR, Morrison CB, Chen G, McFadden KM, Sadritabrizi T, Gutay MI, Kato T, Rogers TD, Snead JY, Livraghi-Butrico A, Button B, Ehre C, Grubb BR, Hill DB, Kelada SNP. BPIFB1 loss alters airway mucus properties and diminishes mucociliary clearance. Am J Physiol Lung Cell Mol Physiol. 2023 Oct 17. doi: 10.1152/ajplung.00390.2022. Epub ahead of print. PMID: 37847709.
  5. Donaldson SH, Corcoran TE, Pilewski JM, Mogayzel P, Laube BL, Boitet ER, Harris ES, Ceppe A, Edwards LJ, Zeman K, Wu J, Esther CR Jr, Nichols DP, Bennett WD, Rowe SM. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis. J Cyst Fibros. 2023 Oct 14:S1569-1993(23)00931-1. doi: 10.1016/j.jcf.2023.10.010. Epub ahead of print. PMID: 37845149.
  6. Zemke AC, Hilliam Y, Stapleton AL, Kimple AJ, Goralski JL, Shaffer AD, Pilewski JM, Senior BA, Lee SE, Cooper VS. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis. Int Forum Allergy Rhinol. 2023 Oct 14. doi: 10.1002/alr.23288. Epub ahead of print. PMID: 37837613.
  7. Despotes KA, Ceppe AS, Donaldson SH. Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis. J Cyst Fibros. 2023 Oct 12:S1569-1993(23)00923-2. doi: 10.1016/j.jcf.2023.10.002. Epub ahead of print. PMID: 37838486.
  8. Cao R, Rossdeutcher RB, Zhong Y, Shen Y, Miller DP, Sobiech TA, Wu X, Buitrago LS, Ramcharan K, Gutay MI, Figueira MF, Luthra P, Zurek E, Szyperski T, Button B, Shao Z, Gong B. Aromatic pentaamide macrocycles bind anions with high affinity for transport across biomembranes. Nat Chem. 2023 Oct 9. doi: 10.1038/s41557-023-01315-w. Epub ahead of print. PMID: 37814114.
  9. Immormino RM, Smeekens JM, Mathai PI, Clough KM, Nguyen JT, Ghio AJ, Cook DN, Kulis MD, Moran TP. Different airborne particulates trigger distinct immune pathways leading to peanut allergy in a mouse model. Allergy. 2023 Oct 7. doi: 10.1111/all.15908. Epub ahead of print. PMID: 37804001.
  10. Peden DB, Almond M, Brooks C, Robinette C, Wells H, Burbank A, Hernandez M, Hinderliter A, Caughey M, Jiang Q, Wang Q, Li H, Zhou H, Alexis N. A pilot randomized clinical trial of γ-tocopherol supplementation on wood smoke-induced neutrophilic and eosinophilic airway inflammation. J Allergy Clin Immunol Glob. 2023 Oct 5;2(4):100177. doi: 10.1016/j.jacig.2023.100177. PMID: 37876758; PMCID: PMC10590746.
  11. Hou YJ, Chiba S, Leist SR, Meganck RM, Martinez DR, Schäfer A, Catanzaro NJ, Sontake V, West A, Edwards CE, Yount B, Lee RE, Gallant SC, Zost SJ, Powers J, Adams L, Kong EF, Mattocks M, Tata A, Randell SH, Tata PR, Halfmann P, Crowe JE Jr, Kawaoka Y, Baric RS. Host range, transmissibility and antigenicity of a pangolin coronavirus. Nat Microbiol. 2023 Oct;8(10):1820-1833. doi: 10.1038/s41564-023-01476-x. PMID: 37749254; PMCID: PMC10522490.
  12. Mayer-Hamblett N, Clancy JP, Jain R, Donaldson SH, Fajac I, Goss CH, Polineni D, Ratjen F, Quon BS, Zemanick ET, Bell SC, Davies JC, Jain M, Konstan MW, Kerper NR, LaRosa T, Mall MA, McKone E, Pearson K, Pilewski JM, Quittell L, Rayment JH, Rowe SM, Taylor-Cousar JL, Retsch-Bogart G, Downey DG. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. Lancet Respir Med. 2023 Oct;11(10):932-944. doi: 10.1016/S2213-2600(23)00297-7. PMID: 37699421.
  13. Ozeri-Galai E, Friedman L, Barchad-Avitzur O, Markovetz MR, Boone W, Rouillard KR, Stampfer CD, Oren YS, Hill DB, Kerem B, Hart G. Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients. Nucleic Acid Ther. 2023 Oct;33(5):306-318. doi: 10.1089/nat.2023.0015. PMID: 37643307.

Filed Under:

Categories: News